Board & Management team

Dimerix has a highly experienced board and management team made up of individuals who have successfully commercialised pharmaceutical products globally. This team is responsible for the strategic direction, operations and success of the Company.

James Williams, PhD, MBA

Non-Executive Chairman

View full biography

View
CLOSE
James Williams, PhD, MBA

James Williams, PhD, MBA

Non-Executive Chairman

James is a Founder and Investment Director of Yuuwa Capital LP, a venture capital firm based in Western Australia and was the CEO of Dimerix between 2007 and 2009. Prior to establishing Yuuwa Capital and managing Dimerix, James was Managing Director of two medical device companies, ASX-listed Resonance Health Ltd and Argus Biomedical Pty Ltd, both of which took their products to market under his guidance. James also co-founded and is a former CSO and Director of iCeutica, Inc., a clinical stage nano drug reformulation company that was acquired in 2011. James is a Director of Yuuwa investee companies Adalta Pty Ltd, PolyActiva Pty Ltd and iCetana Pty Ltd. James is also a Director of Linear Clinical Research Ltd, a specialist early phase clinical trial unit, a member of the “Panel of Experts” for the University of Western Australia’s Pathfinder Fund and a member of the Federal Government’s Entrepreneur Program Committee. James completed his undergraduate degree in Biochemistry at the University of Aberdeen, PhD at Melbourne University and MBA at the University of Western Australia.

Nina Webster, PhD, M IP Law, MBA

Chief Executive Officer / Managing Director

View full biography

View
CLOSE
Nina Webster, PhD, M IP Law, MBA

Nina Webster, PhD, M IP Law, MBA

Chief Executive Officer / Managing Director

Nina has over twenty five years of experience in the pharmaceutical industry, with leadership roles in investor relations, business development, and prosecution of intellectual property matters, as well as leading and managing the strategic, scientific and operational aspects of product development. Nina was formerly the Commercial Director for Acrux Limited (ASX: ACR), an Australian drug pharmaceutical company that has successfully developed and commercialised three products globally. Prior to Acrux, Nina was Director of Commercialisation and Intellectual Property for Immuron Limited (ASX: IMU), and previously spent 6 years in new product development with Wyeth Pharmaceuticals in the UK. Nina holds a Ph.D in Pharmaceutics from Cardiff University, a Bachelor degree in Pharmacology, a Masters degree in Intellectual Property Law from Melbourne University and an MBA from RMIT.

Hamish George, BCom, CA, GIA(Cert)

Chief Financial Officer / Company Secretary

View full biography

View
CLOSE
Hamish George, BCom, CA, GIA(Cert)

Hamish George, BCom, CA, GIA(Cert)

Chief Financial Officer / Company Secretary

Hamish has experience in providing financial advice and CFO services to businesses ranging from small start-ups to large established businesses with turnover of over $50 million. He brings expertise in areas including financial/management reporting, Company Secretarial, cash flow management, taxation including (R&D Tax Incentive), Company Establishments, company valuations, budgeting and forecasting. Hamish is also a member of the senior management team at Bio101, a financial services firm providing outsourced CFO, tax and company secretarial solutions to the life science sector. Hamish holds a Bachelor of Commerce from the University of Melbourne, a Diploma in Financial Planning from Kaplan Professional, a Masters Degree in Professional Accounting from RMIT, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant.

David Franklyn, BEcon

Non-Executive Director

View full biography

View
CLOSE
David Franklyn, BEcon

David Franklyn, BEcon

Non-Executive Director

David has extensive experience in research, financial analysis, funds management and business strategy. David’s career includes 15 years in the Australian stockbroking industry, 10 years in the funds management sector as well as experience in company management and business strategy. He is an experienced company director, having been Chairman, executive director and non-executive director of various ASX listed companies. Most recently, David was Chairman of Onterran Ltd until April 2015. David has strong business management expertise incorporating company restructuring, strategy development, people management, corporate culture and organisational structure. David was recently the managing director of Village National Holdings Limited.

Sonia Poli, PhD

Non-Executive Director

View full biography

View
CLOSE
Sonia Poli, PhD

Sonia Poli, PhD

Non-Executive Director

Sonia is currently Executive Manager at AC Immune, a Nasdaq listed company, and has previously worked within Swiss Stock Exchange listed companies Hoffman la Roche and Addex Therapeutics, where she has held leadership and executive positions across various disciplines in drug discovery, pre-clinical development and translational science and has interacted with regulatory authorities, investors and public funding institutions. Sonia has held various corporate responsibilities such as outsourcing and out-licensing, and she has promoted academic collaborations and supported R&D collaborations with external partners.

Sonia is an accomplished R&D professional with 20 years international experience in large and small pharmaceutical companies. She has broad knowledge of small molecule drug design, optimisation and early clinical development, with expertise which encompasses multiple therapeutic areas.

Sonia is co-author of more than 50 scientific papers and several patents. Sonia holds a Masters degree and a PhD in industrial chemistry from Milan University (IT).

Hugh Alsop BSc (Hons), MBA

Non-Executive Director

View full biography

View
CLOSE
Hugh Alsop BSc (Hons), MBA

Hugh Alsop BSc (Hons), MBA

Non-Executive Director

Hugh is an accomplished pharmaceutical and biotechnology executive with 20 years of experience in international business development, partnering, drug development and leadership of scientific teams. Hugh has demonstrated commercial management skills, profit accountability, and senior oversight of drug development programs for the international market. Hugh has a track record of being part of two significant exit transactions for the Australian life sciences industry, including two successful Phase 3 programs and two FDA approvals for Australian developed products.

Hugh’s most recent role was the Chief Executive Officer of Hatchtech Pty Ltd, where he helped secure a $200 million commercialisation agreement for its lead development product with global Indian pharmaceutical company Dr Reddy’s. In 2010, as Director of Business Development at Acrux Limited, Hugh was a key member of the team that licensed the testosterone product Axiron™, to global pharmaceutical company Eli Lilly for up to US$335m in potential milestones plus royalties.

Robert Shepherd, PhD

Research & Development Director

View full biography

View
CLOSE
Robert Shepherd, PhD

Robert Shepherd, PhD

Research & Development Director

Robert is an experienced pharmaceutical executive having lead multidisciplinary research and development teams for over 11 years. Prior to joining the Dimerix team, Robert was a Senior Development Manager at Medicines Development for Global Health, a non-profit organisation focused on efficiently developing drugs for orphan and neglected indications. In this role, he supported biotechnology and academic groups in project management roles spanning research, manufacturing, nonclinical, clinical and regulatory fields in pain, immunology, infectious diseases, and oncology. Robert has previously held roles as a Business Analyst at the Monash Vision Group, Communications Advisor at the Australian Society of Plant Scientists, and Sessional Lecturer at Monash University. Robert holds a BS in Genetics (Honours), PhD in molecular cell biology and immunology, and a graduate certificate in science commercialisation from Monash University, Australia.

We use our innovative receptor technology in order to uncover pharmaceutical products that will improve patient’s lives.